EU's CHMP negative on Antigenics' therapeutic cancer vaccine Oncophage
This article was originally published in Scrip
Executive Summary
The EU's CHMP has turned down what could have been the first therapeutic cancer vaccine approved in the EU, Antigenics' novel therapy Oncophage (HSPPC-96; vitespen), as an adjuvant treatment for renal cell carcinoma (RCC). The agency said that Oncophage did not demonstrate its effectiveness in prolonging the length of time kidney cancer patients lived without their cancer recurring.